Author

Ting Niu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Real-world treatment patterns and outcomes of brentuximab vedotin–based therapy in CD30-positive lymphomas in China: the prospective BRAVE study

To the Editor Brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, has transformed the treatment landscape through ECHELON trials, including ECHELON-1 in previously untreated advanced-stage classical Hodgkin lymphoma (cHL) [1], ECHELON-2 in peripheral T-cell lymphoma (PTCL) [2], and ECHELON-3 in relapsed...

Ming-Ci Cai, O. Bai, Hui-Lai Zhang et al. · Blood Cancer Journal · 0 citations

Open access Sep 2026

A U‐Shaped Association: The First‐Year eGFR Slope and Mortality Risk in Multiple Myeloma

Renal impairment (RI) increases mortality risk in multiple myeloma (MM), yet RI represents a relatively late stage of kidney dysfunction. Whether early indicators of renal dysfunction, such as the estimated glomerular filtration rate (eGFR slope), predict mortality risk in MM remains unknown.

Lian Li, Xiang Liu, Ming-Jing Guan et al. · Cancer Medicine · 0 citations